公开(公告)号：US07235525B2

公开(公告)日：2007-06-26

申请号：US10516688

申请日：2003-06-06

申请人： Yoshihiro Motomiya ,  Yoshiyuki Moriguchi ,  Hiroyuki Ohkawa

发明人： Yoshihiro Motomiya ,  Yoshiyuki Moriguchi ,  Hiroyuki Ohkawa

IPC分类号： A61K38/00 ,  C07K14/505

CPC分类号： A61K38/1816

摘要： An agent for treatment of metabolic bone disease, which contains EPO as an active ingredient, or a method for treating a patient with metabolic bone disease, which comprises EPO, is provided. Pharmaceutical products containing EPO as the active ingredient are novel prophylactic and therapeutic agents which show an ameliorative action by healing bone and bone marrow lesions in bone disease, especially bone disease based on impaired bone metabolism, aside from the previously reported erythrocyte increasing action of EPO. Pathological states, targeted by these pharmaceutical products, are bone diseases showing metabolic bone disorders, including renal failure-associated osteodystrophy, marble bone disease, diabetic nephropathy, and osteoporosis.

摘要翻译： 提供了包含EPO作为活性成分的用于治疗代谢性骨病的药剂或者包含EPO的用于治疗代谢性骨病的患者的方法。 含有EPO作为活性成分的药物是新的预防和治疗药物，除EPO以前报道的红细胞增加作用外，还可以通过骨骼疾病，特别是基于骨代谢受损的骨病治愈骨和骨髓损伤，显示出改善作用。 这些药物靶向的病理状态是显示代谢性骨病，包括肾衰竭相关性骨营养不良，大理石骨病，糖尿病性肾病和骨质疏松症的骨病。

公开(公告)号：US20050176635A1

公开(公告)日：2005-08-11

申请号：US10516688

申请日：2003-06-06

申请人： Yoshihiro Motomiya ,  Yoshiyuki Moriguchi ,  Hiroyuki Ohkawa

发明人： Yoshihiro Motomiya ,  Yoshiyuki Moriguchi ,  Hiroyuki Ohkawa

IPC分类号： A61K38/18 ,  A61P3/10 ,  A61P13/12 ,  A61P19/00 ,  A61P19/10

CPC分类号： A61K38/1816

摘要： An agent for treatment of metabolic bone disease, which contains EPO as an active ingredient, or a method for treating a patient with metabolic bone disease, which comprises EPO, is provided. Pharmaceutical products containing EPO as the active ingredient are novel prophylactic and therapeutic agents which show an ameliorative action by healing bone and bone marrow lesions in bone disease, especially bone disease based on impaired bone metabolism, aside from the previously reported erythrocyte increasing action of EPO. Pathological states, targeted by these pharmaceutical products, are bone diseases showing metabolic bone disorders, including renal failure-associated osteodystrophy, marble bone disease, diabetic nephropathy, and osteoporosis.

摘要翻译： 提供了包含EPO作为活性成分的用于治疗代谢性骨病的药剂或者包含EPO的用于治疗代谢性骨病的患者的方法。 含有EPO作为活性成分的药物是新的预防和治疗药物，除EPO以前报道的红细胞增加作用外，还可以通过骨骼疾病，特别是基于骨代谢受损的骨病治愈骨和骨髓损伤，显示出改善作用。 这些药物靶向的病理状态是显示代谢性骨病，包括肾衰竭相关性骨营养不良，大理石骨病，糖尿病性肾病和骨质疏松症的骨病。